Intellia Therapeutics, Inc. (NTLA) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -609.9%, revenue growth -46.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $67.67M |
| Revenue (TTM) | $0.1B |
| Net Margin | -609.9% |
| Return on Equity | -55.0% |
| Operating Margin (TTM) | -711.7% |
| Current Ratio | 6.65 |
| Revenue Growth (YoY) | -46.2% |
| EPS Growth (YoY) | -18.4% |
| FCF Growth (YoY) | -15.0% |
| Price / Book | 2.26 |
| Price / Sales | 27.65 |
| FCF Yield | -21.2% |
| Altman Z-Score | -0.48 (distress) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
NTLA overview · NTLA earnings · NTLA KPIs · NTLA documents · NTLA ownership · NTLA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.